title: Impact of oral bases on aluminum absorption.
abstract: Control of hyperphosphatemia in renal failure is often difficult to achieve. Although calcium-containing phosphate binders have become the preferred phosphate binders, many patients require the addition of an aluminum-containing phosphate binder (APB). Enhanced aluminum absorption has been noted when APBs are administered with citrate-containing products such as citrate/citric acid solution (CCA). Alternative phosphate binders such as calcium acetate may also increase aluminum absorption. This study investigated the effect of CCAs on aluminum absorption when aluminum antacids (APBs) were administered concurrently and 2 hours apart. The effects of the alternative alkalinizing agent sodium bicarbonate and the alternate phosphate binding agent calcium acetate on aluminum absorption were also studied. During five 2-day phases, ten normal volunteers randomly received three times daily with standardized meals aluminum hydroxide alone and concurrently with NaHCO3, calcium acetate, CCA, or with CCA 2 hours postprandially. Twenty-four hour urines were collected on the second day of each phase and aluminum excretion was determined using inductively coupled plasma emission spectroscopy. Urine aluminum excretion was statistically significantly (P <.005) elevated in subjects receiving Al(OH)3 and CCA both with meals, 269.3 +/- 146.3 microg/d, and 2 hours after meals, 303.3 +/- 142.9 microg/d, compared with 79.2 +/- 52.0 microg/d during treatment with Al(OH)3 alone. Administration of CCA 2 hours after APB does not permit the safe use of these agents concurrently. Concomitant administration of sodium bicarbonate and calcium acetate with APBs appears to be safe, as aluminum absorption was not affected.
authors: College of Pharmacy and Medical College of Ohio, Toledo, OH, USA.
authors: L S
authors: LS
authors: Mauro
authors: D A
authors: DA
authors: Kuhl
authors: J R
authors: JR
authors: Kirchhoff
authors: V F
authors: VF
authors: Mauro
authors: R W
authors: RW
authors: Hamilton
mesh_terms: D000042:Absorption; D000085:Acetates / Q000494:pharmacology; D000284:Administration, Oral; D000328:Adult; D000535:Aluminum / Q000493:pharmacokinetics* / Q000652:urine; D000536:Aluminum Hydroxide / Q000008:administration & dosage; D000863:Antacids / Q000493:pharmacokinetics*; D017610:Calcium Compounds; D002614:Chelating Agents / Q000494:pharmacology*; D019343:Citric Acid / Q000494:pharmacology*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D006801:Humans; D008297:Male; D010710:Phosphates / Q000652:urine; D051437:Renal Insufficiency / Q000150:complications; D017693:Sodium Bicarbonate / Q000494:pharmacology
chemical_list: D000085:Acetates; D000863:Antacids; D017610:Calcium Compounds; D002614:Chelating Agents; D010710:Phosphates; D019343:Citric Acid; D000536:Aluminum Hydroxide; D017693:Sodium Bicarbonate; D000535:Aluminum; C120662:calcium acetate